Business, energy, technology, markets and global industry news from Business News Today

Phase 2 trials

PharmaDeviceNews Phase 2 trials
Representative image: Oncology researchers reviewing head and neck cancer imaging data, reflecting the clinical focus of Inhibrx Biosciences’ INBRX-106 HexAgon study update in first-line HNSCC and the broader immuno-oncology race to improve pembrolizumab-based treatment strategies.
Pharma & Biotech

Inhibrx’s HexAgon study may test whether smarter OX40 design can beat old failures

OX40 biology has promised more than it proved. Inhibrx now needs INBRX-106 to show pembrolizumab can work harder in HNSCC.

Read More
Pharma & Biotech

Why DemeRx’s FDA-cleared DMX-1001 IND could matter for alcohol use disorder drug development

Find out how DemeRx’s DMX-1001 IND acceptance could reshape alcohol use disorder drug development and what risks remain.

Read More
Pharma & Biotech

Elunetirom shows synaptogenic promise as Autobahn eyes pivotal trials in depression

Autobahn’s elunetirom may offer a novel neuroplasticity-driven treatment for depression. Find out what its latest data mean for the future of MDD therapy.

Read More